Electrocore's Truvagatm Plus Named“Best Relaxation Gadget” In Esquire's 2025 Sleep Awards

(MENAFN- GlobeNewsWire - Nasdaq) ROCKAWAY, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TruvagaTM Plus handheld vagus nerve stimulation (nVNS) device has been named the“ Best Relaxation Gadget ” in Esquire's 2025 Sleep Awards.

The annual Sleep Awards from Esquire recognize the most effective and innovative solutions for improving rest and recovery. Truvaga Plus was selected by the magazine's editors after extensive hands-on testing, earning recognition for its ability to calm the nervous system, reduce stress, and promote restorative sleep in just two-minute sessions.

“We are honored to be recognized in Esquire's Sleep Awards,” said Kelly Benning, Senior Vice President of Truvaga at electroCore.“This recognition is a powerful validation for Truvaga Plus. Sleep is one of the most universal health challenges people face, and having an independent editorial team highlight our device builds confidence for consumers seeking a proven, drug-free way to relax, recharge, and sleep better.”

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company's two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit .

About Truvaga Plus

Truvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company's proven technology to quickly and gently activate the vagus nerve. It's designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease.

• Backed by 20+ years of research in bioelectronic medicine
• Made in the USA and Shipped from the USA
• Drug-free and non-invasive technology for stress relief and sleep
• Quick two-minute sessions that fit easily into daily routines
• 30-Day risk-free trial available at
  

Truvaga Plus stands out as one of the few consumer wellness devices that leverages vagus nerve stimulation science, offering a natural alternative to medications and supplements for relaxation and sleep.

For more information on Truvaga Plus, or to purchase directly, visit .

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the anticipated results from being Named“Best Relaxation Gadget” in Esquire's 2025 Sleep Awards, the benefits of Truvaga Plus, the Company's future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as“anticipates,”“will,”“expects,”“believes,”“intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore's results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at

Contact:

ECOR Investor Relations
(973) 302-9253
...

ECOR Media Relations
(973) 435-8354
...

MENAFN22092025004107003653ID1110093586